Economy/Home · Economy

SCL Science (246960) Expands Hemostatic Agent Indications and Develops Cancer Vaccines... Kiwoom Securities Foresees 'Comprehensive Healthcare Company'

Securities analysts say that SCL Science (246960) is continuing its transformation into a comprehensive healthcare company, expanding its business scope from bio logistics, health checkups, and digital transformation (DX) to hemostatic agents and cancer vaccine development. Kiwoom Securities evalua

Wooil Shim
Staff Reporter
5 min read
SCL Science (246960) Expands Hemostatic Agent Indications and Develops Cancer Vaccines... Kiwoom Securities Foresees 'Comprehensive Healthcare Company'
CBC News

Securities analysts say that SCL Science (246960) is continuing its transformation into a comprehensive healthcare company, expanding its business scope from bio logistics, health checkups, and digital transformation (DX) to hemostatic agents and cancer vaccine development.

Kiwoom Securities evaluated SCL Science as a comprehensive healthcare company encompassing bio logistics and health checkups, DX and AX businesses including remote diagnosis reading, C-LAB CRO, and cancer vaccine development. According to the company, SCL Science has expanded its business portfolio by adding various new businesses, while also continuing the development of hemostatic agents, the foundation of its existing business.

■ Hemostatic agents: expanded indications create growth momentum

The hemostatic agent business recently gained momentum for expansion. According to Kiwoom Securities, SCL Science obtained domestic approval in February 2025 and expanded its indications through an approval change in May 2026. As a result, the applicable medical areas have broadened, raising the possibility of increased related sales going forward.

■ Cancer vaccines under development based on mRNA and peptide platforms

In terms of new drug development, the cancer vaccine business is cited as another growth axis. As global pharmaceutical company Moderna has achieved results in developing mRNA-based cancer vaccines, attention to the related market has grown, and SCL Science is also developing mRNA- and peptide-based cancer vaccines through its subsidiary.

However, cancer vaccines are a field where business value can vary significantly depending on the clinical development process and regulatory approval. Before actual commercialization, it is necessary to continuously verify data from each clinical stage, development timelines, and the scale of capital investment.

■ Key variables for future performance

Looking at SCL Science's performance outlook, the key variables will be whether the expanded indications for hemostatic agents translate into actual sales growth, along with the growth of the healthcare services business and the development progress of the cancer vaccine pipeline.

[Stock prices may exhibit increased volatility depending on corporate performance, industry conditions, merger terms, and market supply and demand. Securities firms' analyses and forecasts may differ from actual future results and do not guarantee returns on specific stocks. Before making investment decisions, it is necessary to comprehensively review the company's official disclosures, financial condition, and business progress. This article is not intended to recommend the purchase or sale of any specific stock. This article was written with AI assistance.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.